GLUD1 inhibition might be ineffective in pancreatic cancer, since oncogenic KRASG12D has been suggested to inhibit GLUD1 and preferentially activate the noncanonical glutaminolysis pathway. This evidence concerns the gene GLUD1 and familial pancreatic carcinoma.